{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Week in Review Desk", "lead_paragraph": "AT a hearing Thursday on Capitol Hill, senators excoriated top federal drug regulators for failing to realize three years ago that Vioxx, a pain pill that Merck withdrew in September, was dangerous. But the Food and Drug Administration today faces almost exactly the same situation with another arthritis drug, Bextra, that it did with Vioxx three years ago. And just as with Vioxx, it is far from clear what the agency should do. In a sign that they believe they acted appropriately in the Vioxx case, top agency officials are handling the Bextra situation exactly the same way.", "headline": {"main": "Ideas & Trends; Shades of the Vioxx Case for Another Drug"}, "abstract": "Senators at recent hearing excoriated top federal drug regulators for failing to realize three years ago that Vioxx, pain pill that Merck & Co withdrew in Sept, was dangerous; Food and Drug Administration faces almost same situation with another arthritis drug, Bextra; Pfizer, Bextra's maker, defends its drug just as Merck did; studies of Bextra provide ammunition to both sides; two studies of Bextra sponsored by Pfizer showed that it increased risks of heart attack and stroke among patients undergoing cardiac surgery; FDA has asked panel of independent experts to examine studies of Bextra and tell agency what to do; photo (M)", "print_page": "3", "word_count": 822, "_id": "4fd280928eb7c8105d84bab3", "snippet": "The Food and Drug Administration faces almost exactly the same situation with the arthritis drug Bextra that it did with Vioxx three years ago.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/21/weekinreview/21harr.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "BEXTRA (DRUG)"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "SURGERY AND SURGEONS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-11-21T00:00:00Z", "section_name": "Health; Week in Review"}, {"type_of_material": "News", "blog": [], "news_desk": "Magazine Desk", "lead_paragraph": "Looking back, Mark and Cheryl Miller would have done a lot of things differently with their 13-year-old son, Matt. They probably would never have left Lenexa, Kan. They would have sent him to a different school, and they certainly would have chosen a different therapist. But most of all, they wouldn't have given him Zoloft. ''It's not a pleasant thing living with the thought that you had a hand in your son's death,'' Mark Miller told me recently. ''Making him take those pills was done out of love for Matt, but it was still the wrong thing to do.'' We were on our way back from Mark and Cheryl's Wednesday-night Bible-study class. I was riding with Mark, who had come straight from the advertising agency where he works as a vice president and creative director. A young-looking 55, with neatly combed hair and wire-rimmed glasses, he was wearing a striped Polo button-down and pressed blue jeans. A few minutes later Mark eased his white Volvo into the garage of their home, a meticulously decorated two-story Tudor in Overland Park, Kan. The Millers moved here from Lenexa, like Overland Park a suburb of Kansas City, in the summer of 1996, though they'd been talking about relocating for years. They liked Lenexa, but Mark was doing well, and they could afford a bigger house in a more upscale neighborhood.", "headline": {"main": "The Antidepressant Dilemma"}, "abstract": "Jonathan Mahler article explores use of antidepressants by teenagers, in light of FDA finding that they may trigger suicidal thoughts in that age group; cites case of Matt Miller, 13, who killed himself after just several days on Zoloft, and lawsuit filed by his parents against Pfizer; question is complicated by fact that patients who are prescribed antidepressants are, by definition, vulnerable to suicidal behavior, making it difficult to determine where effects of depression end and where effects of drug begin; many child psychiatrists believe FDA overreached in its decision, leaving them with few tools to combat teenage mental health problems; photos (L)", "print_page": "59", "word_count": 7665, "_id": "4fd280928eb7c8105d84ba98", "snippet": "Since the F.D.A. has issued a strong warning about adolescent use of antidepressants, will the inevitable decrease in prescriptions ultimately lead to more teenage suicides?", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/21/magazine/21TEENS.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "ZOLOFT (DRUG)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Jonathan", "rank": 1, "lastname": "Mahler"}], "original": "By Jonathan Mahler"}, "document_type": "article", "pub_date": "2004-11-21T00:00:00Z", "section_name": "Health; Magazine"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Every few years, a whistle-blower arrives on Capitol Hill and shakes up a federal agency with charges of incompetence and misfeasance. On Thursday, Dr. David J. Graham of the Food and Drug Administration had his turn. Using colorful metaphors and an advocate's passion, he said his agency was ''incapable of protecting America'' against dangerous drugs. He charged that those inside the agency who had reviewed the safety of Vioxx, the painkiller withdrawn from the market in September, ''did a terrible job.'' He called for a complete overhaul of the way the agency reviews the safety of marketed drugs.", "headline": {"main": "A Firebrand on Drug Safety; Dr. David J. Graham", "kicker": "Man in the News"}, "abstract": "Man in News column on Dr David J Graham of Food and Drug Administration; Graham recently told Senate panel that his agency is incapable of protecting America against dangerous drugs; he charged that those inside agency who had reviewed safety of Vioxx, painkiller withdrawn from market in Sept, 'did a terrible job'; photo (M)", "print_page": "16", "word_count": 984, "_id": "4fd280928eb7c8105d84ba87", "snippet": "The F.D.A. scientist who told Congress that the agency was \"incapable of protecting America\" against dangerous drugs is widely acknowledged as sharp and well prepared.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/20/national/20fda.html", "multimedia": [{"url": "images/2004/11/20/national/20fba.751.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/11/20/national/20fba.751.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "MAN IN THE NEWS (TIMES COLUMN)"}, {"name": "persons", "value": "GRAHAM, DAVID J"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "subject", "value": "ACCIDENTS AND SAFETY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-11-20T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Metropolitan Desk", "lead_paragraph": "Warfare is so brutal that it is easy to understand the cynicism that doubts whether the words war and morality even belong in the same sentence. That is not the way that the military looks at it, however. In the years since the war in Vietnam and revulsion at events like the My Lai massacre, leadership of the armed forces has probably been way ahead of civilian policy makers in giving heed to traditional standards of ethical conduct in battle. No one imagines that these standards will be perfectly observed in the heat of combat, but they provide precious barriers against the descent into utter inhumanity.", "headline": {"main": "In the brutality of war, the innocents have become lost in the crossfire.", "kicker": "Beliefs"}, "abstract": null, "print_page": "6", "word_count": 1010, "_id": "4fd280238eb7c8105d84b24b", "snippet": "Warfare is so brutal that it is easy to understand the cynicism that doubts whether the words war and morality even belong in the same sentence.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/20/national/20beliefs.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "WAR AND REVOLUTION"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Peter", "rank": 1, "lastname": "Steinfels"}], "original": "By Peter Steinfels"}, "document_type": "article", "pub_date": "2004-11-20T00:00:00Z", "section_name": "New York and Region"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The United States and Australia announced on Thursday that they had resolved the remaining disputes in a free trade agreement reached earlier this year. Australia agreed to make at least a half-dozen changes requested by the United States covering intellectual property rights, but resisted making several other changes involving drug benefits and pricing.", "headline": {"main": "U.S. and Australia Resolve Disputes in a Trade Agreement"}, "abstract": "US and Australia announce they have resolved remaining disputes in free trade agreement; Australia agrees to make at least half-dozen changes requested by US covering intellectual property rights but resists other changes involving drug benefits and pricing (M)", "print_page": "7", "word_count": 365, "_id": "4fd254e58eb7c8105d7fce05", "snippet": "Australia agreed to make changes requested by the U.S. covering intellectual property rights, but resisted making changes involving drug benefits and pricing.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/19/business/worldbusiness/19trade.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "AUSTRALIA"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "CUSTOMS (TARIFF)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Elizabeth", "rank": 1, "lastname": "BECKER"}], "original": "By ELIZABETH BECKER"}, "document_type": "article", "pub_date": "2004-11-19T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Nearly a year before Merck received results from the clinical trial that prompted the company to withdraw its painkiller Vioxx from the market, the company received preliminary results from a separate study of patient records that also apparently indicated that the drug posed cardiovascular risks. Merck has not publicly disclosed that separate study's results or referred to it in any of its statements about Vioxx's safety record since announcing in late September that it would stop selling the drug. But a company spokeswoman, in response to a reporter's questions yesterday, confirmed the study's existence and said that Merck, which paid for the research, received its preliminary results last November -- and was given a final report 10 days before the company announced it would stop selling Vioxx.", "headline": {"main": "Earlier Merck Study Indicated Risks of Vioxx"}, "abstract": "Nearly year before Merck received results from clinical trial that prompted company to withdraw its painkiller Vioxx from market, company received preliminary results from seprate study of patients records that also apparently indicated that drug posed cadiovascular risks; Merck has not publicly disclosed that separate study's results or referred to it in any of its statements about Vioxx's safety record since announcing in late September that it would stop selling drug; company spokeswoman Wainwright confirms study's existence and says Merck, which paid for research, received its preliminary results last November, and was given final report 10 days before company anounced it would stop selling Vioxx; says separate study, because it was based on patient records and not actual clinical trial, was inconclusive and had no bearing on decision to withdraw Vioxx; chief executive Raymond V Gilmartin is expected to be questioned on matter in hearing by Senate Finance Committee, which will also be examining Food and Drug Administration's handling of Vioxx and other drug issues; photo (M)", "print_page": "1", "word_count": 1095, "_id": "4fd25a678eb7c8105d806e25", "snippet": "Nearly one year ago, Merck received preliminary results from a study of patient records that apparently indicated Vioxx posed cardiovascular risks.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/18/business/18vioxx.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "GILMARTIN, RAYMOND V"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Barry", "rank": 1, "lastname": "MEIER"}], "original": "By BARRY MEIER"}, "document_type": "article", "pub_date": "2004-11-18T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Nine months ago, the United States and Australia completed negotiations on a landmark trade agreement that won unusually broad bipartisan support in Congress. But a dispute over drugs, both prescription and generic, is threatening to delay the effective date of Jan. 1. Prime Minister John Howard of Australia has become one of Mr. Bush's strongest allies, one of the few who sent troops to Iraq, and the trade agreement is meant to draw the countries even closer together.", "headline": {"main": "Drug Dispute Snags U.S.-Australia Pact"}, "abstract": "Dispute over prescription and generic drugs threatens to delay January 1 implementation of landmark US-Australian trade agreement; agreement, which promises $2 billion year in new industrial exports and possible creation of new jobs, has been dogged by disputes over ability of American pharmaceutical companies to challenge decisions about which drugs will be covered, and at what prices, under Australia's national health insurance program (M)", "print_page": "1", "word_count": 1038, "_id": "4fd2a5628eb7c8105d88c90d", "snippet": "Nine months ago, the United States and Australia signed a landmark trade agreement. But a dispute over drugs, both prescription and generic, is threatening to delay the Jan. 1 effective date.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/17/business/worldbusiness/17australia.html", "multimedia": [{"url": "images/2004/11/17/business/18australian.gif", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/11/17/business/18australian.gif"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "glocations", "value": "AUSTRALIA"}, {"name": "organizations", "value": "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "CUSTOMS (TARIFF)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Elizabeth", "rank": 1, "lastname": "BECKER"}, {"organization": "", "role": "reported", "firstname": "Robert", "rank": 2, "lastname": "PEAR"}], "original": "By ELIZABETH BECKER and ROBERT PEAR"}, "document_type": "article", "pub_date": "2004-11-17T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "We were at the county fair the night I realized my 8-year-old was having panic attacks. She and her 13-year-old sister had gone on a ride, the kind where a round room spins, the floor drops away and centrifugal force holds the riders to the walls. I stood outside and watched the ride start to spin and then, puzzlingly, slow down.", "headline": {"main": "A Panicked Child, a Worried Parent, a Controversial Pill", "kicker": "CASES"}, "abstract": "Harriet Brown Cases column describes child who, after recovering from serious illness, developed panic attacks and displayed changes in behavior; parents consulted with doctor and treated child with antidepressant Prozac; ethics and medical concerns about prescribing antidepressants for children discussed; drawing (M)", "print_page": "5", "word_count": 839, "_id": "4fd254e58eb7c8105d7fcdcc", "snippet": "When a young child is experiencing panic attacks, what is a parent to do?", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/16/health/16case.html", "multimedia": [{"url": "images/2004/11/15/health/16case.75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/11/15/health/16case.75.jpg"}, "type": "image", "height": 75}, {"subtype": "tiny_thumb", "legacy": {"tinythumbwidth": 55, "tinythumbheight": 55, "hastinythumb": "Y"}, "type": "image", "width": 55, "height": 55}], "subsection_name": null, "keywords": [{"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "PROZAC (DRUG)"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Harriet", "rank": 1, "lastname": "BROWN"}], "original": "By HARRIET BROWN"}, "document_type": "article", "pub_date": "2004-11-16T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "Even though colds are called colds, most people know that viruses are to blame, not the temperature. But a small group of people come down with fevers when they experience chills, according to an article published on Saturday in The Lancet, the medical journal. One of the study's authors, Dr. Hal Hoffman of the University of California at San Diego, estimates that about 300 people, most in the United States, suffer from the disorder, familial cold autoinflammatory syndrome, or F.C.A.S., which is caused by a single genetic mutation.", "headline": {"main": "It's Not the Cold, It's the Chill", "kicker": "VITAL SIGNS: CAUSE AND EFFECT"}, "abstract": "Dr Hal Hoffman of University of California at San Diego authors study published in journal Lancet that clarifies genetic illness called familial cold autoinflammatory syndrome; study reports on tests involving drug anakinra and finds it successful in treating fevers and rashes after exposure to cold; drawing (M)", "print_page": "6", "word_count": 299, "_id": "4fd23f1e8eb7c8105d7d645b", "snippet": "A disorder causes some people to come down with fevers when they experience chills, according to a new article.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/16/health/16caus.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "HOFFMAN, HAL"}, {"name": "organizations", "value": "LANCET"}, {"name": "organizations", "value": "UNIVERSITY OF CALIFORNIA"}, {"name": "subject", "value": "FEVER"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ANAKINRA (DRUG)"}, {"name": "subject", "value": "VIRUSES"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "John", "rank": 1, "lastname": "O'Neil"}], "original": "By John O'Neil"}, "document_type": "article", "pub_date": "2004-11-16T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 9, "offset": 0, "time": 50}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}